COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01804985
Recruitment Status : Unknown
Verified May 2017 by Professor Richard E Clark, University of Liverpool.
Recruitment status was:  Active, not recruiting
First Posted : March 5, 2013
Last Update Posted : May 4, 2017
Newcastle University
Imperial College London
University of Glasgow
Information provided by (Responsible Party):
Professor Richard E Clark, University of Liverpool